PI3K INHIBITION WITH THE KETOGENIC DIET IN PEDIATRIC HIGH-GRADE GLIOMA

PI3K INHIBITION IN CONJUNCTION WITH THE KETOGENIC DIET REDUCES GROWTH AND NEUROINFLAMMATION IN PEDIATRIC HIGH-GRADE GLIOMA


Professor Lewis Cantley is also involved in pre clinical research in pediatric high-grade glioma.
His decision to use paxalisib as his preferred PI3K inhibitor in the new phase2 glioblastoma trial announced today, is another vote of confidence for our drug.

https://academic.oup.com/neuro-oncology/article-abstract/21/Supplement_6/vi89/5619560?redirectedFrom=fulltext

Regards.